← Leaderboards
Lawrence A Quilliam
Indiana Univ-Purdue Univ At Indianapolis
$1,163,919
Attributed
$1,163,919
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $258.7K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,163,919 · 1
By mechanism
R01$1,163,919 · 1
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Kenneth P Nephew$7,005,060
- David A Williams$57,290,422
- Joseph R Dynlacht$3,042,476
- David A Ingram$3,588,412
- Nyla A. Heerema$1,072,594
Others in their field
Top investigators on “Epidermal Growth Factor Receptor”
- Norman Wolmark · Nsabp Foundation, Inc.$27,726,714
- Walter John Curran · Thomas Jefferson University$26,641,549
- Robert J Coffey · Vanderbilt University$24,542,527
- Pasi A Janne · Stanford University$23,416,433
- John H Sampson · Duke University$21,673,210
- Jennifer R Grandis · University Of Pittsburgh At Pittsburgh$19,623,343
Research focus
Epidermal Growth Factor ReceptorDesignApoptosisDominant-Negative MutationAbnormal CellBiologicalBrainAttenuatedCancer CellBaseCancer TherapyBinding (Molecular Function)Cell Cycle RegulationCell GrowthCell Growth RegulationCell LineBrain NeoplasmsCell PhysiologyCellsChemotherapeutic AgentCollectionCancer Cell LineDefectEvent
Grant awards (5)
Rheb GTPase as chemotherapeutic target for brain tumors$224,630
R01 · FY2009 · CA · contact PI
Rheb GTPase as chemotherapeutic target for brain tumors$224,630
R01 · FY2008 · CA · contact PI
Rheb GTPase as chemotherapeutic target for brain tumors$224,630
R01 · FY2007 · CA · contact PI
Rheb GTPase as chemotherapeutic target for brain tumors$231,339
R01 · FY2006 · CA · contact PI
Rheb GTPase as chemotherapeutic target for brain tumors$258,690
R01 · FY2005 · CA